Resources - Application Notes
Automated Kinetic Imaging Assay of Cell Proliferation in 384-Well FormatDownload
Related Products: BioSpa 8, BioSpa System , Cytation 5, Cytation 7
December 26, 2019
Image-based kinetic analysis of cell proliferation and cell death mechanisms
Author: Rebecca Mongeon, Ph.D., Agilent Technologies, Inc
Evasion of cell death is a hallmark of cancer cells that allows them to overcome endogenous barriers to cancer development, as well as to resist treatment. Understanding how cancer cells are able to evade cell death promises to unlock new avenues to treat human cancer. Here we present a fully automated image-based assay to monitor both the proliferation and cell death of a fibrosarcoma cancer cell line in response to multiple anti-neoplastic drugs in a high-throughput format.
Even from the beginning of life, the proper function of all multi-cellular organisms depends on cell death. Mismanaged cell death underlies phenomena ranging from developmental abnormalities to cancer. The ability of cancerous cells to evade regulated cell death, or apoptosis, is particularly problematic for cancer treatment1. Whether through radiation, immunotherapy or chemotherapy, the goal of cancer treatment is the selective death of the cancerous cells. Understanding the many facets of cell death, and in particular those aspects that cancer cells are able to overcome, is an active area of interest for clinicians, primary researchers and drug discovery efforts alike1. Imaging-based tools to monitor cells undergoing different cell death mechanisms have provided a means to probe cell death in a continuous, live, high-throughput manner.
Regulated cell death, such as apoptosis, and accidental cell death, such as necrosis, are both processes that can occur in response to a cellular stressor (ie. nutrient deprivation or DNA damage), but each produce different hallmark cellular changes2. One of the characteristics of early state apoptosis occurs when phosphatidylserine, a membrane component normally only found within the inner leaflet of cell membranes, translocates to the outer leaflet. This exposure of phosphatidylserine likely prompts engulfment of the cell, or remaining cell fragments, by phagocytes3. Here, we optically monitor phosphatidylserine exposure in live cells through its specific binding and activation of the fluorescent pSIVA-IANBD probe. This fluorescent probe provides a live, kinetic indicator of cells undergoing apoptosis and persists through cell death4.
A characteristic change during both late-stage apoptosis and necrosis processes is that cell membrane integrity is lost2. This loss of integrity allows molecules that are normally excluded to enter cell nuclei, such as the DNA staining dye propidium iodide (PI). Therefore, fluorescent PI staining of nuclei can also be monitored in real-time as a measure of cells undergoing necrosis and late-stage apoptosis processes.
This study combined long-term kinetic label-free cell counting and fluorescent imaging to monitor cancer cell responses over several days in a high-throughput 384-well image-based assay. The Agilent BioTek Cytation 5 cell imaging multimode reader with a wide field of view camera enables capture of the entire 384-well in a single image. Coupling the Cytation 5 with the Agilent BioTek BioSpa 8 automated incubator for fully automated environmental control enabled a walk-away workflow of high-throughput image-based cellular analysis.
Materials and methods
HT-1080 fibrosarcoma cells were obtained from ATCC (Manassas, VA). Advanced DMEM, Fluorobright DMEM, fetal bovine serum (FBS), and glutamine/penicillin/streptomycin were purchased from Thermo Fisher Scientific (Waltham, MA). Staurosporine, nocodazole, nigericin and camptothecin were purchased from Tocris Bioscience (Minneapolis, MN). The Kinetic Apoptosis kit for microscopy (ab129817) was purchased from Abcam (Cambridge, MA). Greiner 384-well microplates (part number 781091) were obtained from Sigma-Aldrich (St. Louis, MO).
Cell culture and assay preparation
HT-1080 cells were maintained in Advanced DMEM media supplemented with 10% FBS, 2 mM glutamine and penicillin/streptomycin at 37 °C in a humidified incubator with 5% CO2. Cells were routinely passaged at 80% confluency. For seeding in 384-well microplates, HT-1080 cells were harvested and suspensions were added at a density of 500 cells per well. After cells adhered (approximately 4 hours), media was exchanged for Fluorobrite DMEM media. The kinetic apoptosis kit reagents were added to each well to a final concentration of 1 µL/mL pSIVA-IANBD and 2 µL/mL PI. Dilution series of antineoplastic drugs were added across the microplate, and imaging was started immediately following drug addition.
Automated long-term live-cell imaging
For fully automated long-term imaging, cells were maintained in a BioSpa 8 automated incubator that was coupled to a Cytation 5 cell imaging multimode reader with a wide field of view camera. The BioSpa maintained cells at 37 °C, 5% CO2 and 80 to 90% humidity throughout the course of the 72-hour experiment, and environmental parameters were monitored and reported live through Agilent BioTek BioSpa software. The microplate was automatically transferred from the BioSpa incubator to the Cytation 5 at two-hour intervals for imaging. Additional environmental controls inside the Cytation 5 maintained cells at 37 °C and 5% CO2 throughout the imaging procedure.
Single image whole-well capture
For whole-well imaging of the 384-well microplate, the Cytation 5 with wide-field-of-view camera was paired with a 4x magnification objective. The Cytation 5 wide-field-of-view enabled a single-image capture of the entire culture area of the well (see Figure 1). The Cytation 5 was configured for imaging as shown in Table 1. Imaging cubes GFP (469/525 nm) and PI (531/647 nm) were used for detection of kinetic apoptosis kit reagents pSIVA and PI signals, respectively. For label-free cell counting, the Cytation 5 with high contrast brightfield was used as described previously5.
Table 1. Agilent BioTek Gen5 software settings for image acquisition.
Image processing was performed using Gen5 software and the parameters used are listed in Table 2. Preprocessing reduced background and enhanced contrast, readily enabling cell identification in all channels. For the high contrast brightfield image, processing results in an image with a black background, and bright white spots corresponding to cells.
Table 2. Agilent BioTek Gen5 software image processing parameters.
Cellular analysis was performed on preprocessed images and the parameters for all channels used are listed in Table 3. For each channel, the threshold value was determined through the image statistics analysis in Gen5. Image statistics of control wells was carried out, and three standard deviations above the average image signal was used as the threshold value for cellular analysis. Total cell counts were established through primary mask analysis of the high-contrast brightfield image. The number of cells positive for the apoptotic reporter pSIVA was established through primary mask analysis of the GFP channel. The number of cells positive for the necrotic marker, PI, was established through primary mask analysis of the PI channel. The liquid meniscus introduced an imaging artifact where the corners of the square well were slightly less illuminated in brightfield than the rest of the culture area (see Figure 1), potentially introducing bias in the label-free cell counts compared to fluorescence counts. The Gen5 plug feature was used to restrict cellular analysis to the area of the well best illuminated in brightfield (a 3,400 µm diameter circle), corresponding to ~92% of the total well culture area. Therefore, the plug feature enabled unbiased normalization of fluorescent cell counts using label-free cell counting methods.
Table 3. Agilent BioTek Gen5 software cellular analysis parameters.
Curve fitting and statistics
All data were collected and analyzed using Agilent BioTek Gen5 software. For data presentation, both Gen5 and GraphPad Prism V8 software were used. All curve fitting and EC50 analysis was performed in Gen5. Time of Vmax analysis in Gen5 was performed over a 5-point window for linear regression. Statistical analysis was performed using the Student’s t-test function (two-tailed, unpaired) in Microsoft Excel.
Results and discussion
Automated kinetic analysys of proliferation
Label-free image-based cell counting of the human fibrosarcoma cell line HT-1080 was performed at two hour intervals over three days in a 384-well plate. For each well, a single image was captured using a 4x objective and the High Contrast Brightfield kit. Cell counts were established using cellular analysis in Gen5 (Figure 1).
Figure 1. Label-free high contrast cell counting method. (A) Original high contrast defocused image captured with the high contrast kit. Total culture area of a single well of the 384-well plate is outlined in dashed blue line. (B) High contrast brightfield image after preprocessing steps indicated in Table 2. (C) Agilent BioTek Gen5 cellular analysis software identifies and counts HT-1080 cells (yellow), shown overlaid on original high contrast brightfield image.
The effect on cell proliferation of four anti-neoplastic drugs: staurosporine, nocodazole, camptothecin and nigericin was examined. The drugs were added just before the first images were acquired at t=0 hours. Gen5 software generated curves of cell counts providing a visual overview of proliferation rates for the entire 384-well dish (Figure 2). The differential inhibitory effect of each drug on proliferation was readily appreciated in the Gen5 plate overview.
Figure 2. 384-well plate overview of cell proliferation. Red curves indicate cell count plotted over the duration of the 3 day experiment. As drug concentration increases from rows C through P, reduced proliferation is observed for all drugs across the entire 384-well plate.
For two example drugs, nocodazole and camptothecin, cell counts are plotted together across the different doses (Figure 3A, 3B). For all further analysis, replicates of 12 wells for each condition were averaged and plotted together. To quantify the inhibitory effect of each drug on proliferation, dose-response curves were generated in Gen5 (Figure 3C, 3D). Dose-response curves were first generated for different drugs through single time point analysis at 24 hours.
Figure 3. Dose-dependent inhibition of HT-1080 fibrosarcoma cell proliferation. Average cell count plots are overlaid for several concentrations of (A) nocodazole (orange circles, n = 12 replicate wells) and (B) camptothecin (green circles, n = 12 replicate wells) over three days. Error bars indicate standard deviation of replicates. Agilent BioTek Gen5 generated dose-response curves for label-free cell counts at a single time point of 24 hours for (C) nocodazole (orange circles) and (D) camptothecin (green circles). The 4-parameter fits are indicated in black solid lines, and interpolated IC50 values are visualized with dashed lines. For nododazole, the IC50 corresponds to 48 nM, and for camptothecin corresponds to 12 nM.
Gen5 provides an additional comparison of IC50 values from integral analysis of the area under the curve (Figure 4). This way of calculating IC50 values was independent of drug exposure time, and accounted for changes across the duration of the experiment. For camptothecin, IC50 values were in good agreement between analysis methodologies. For comparison, AUC analysis was also done for nigericin and nocodozole, demonstrating assay sensitivity across large variations in IC50 (Figure 4, panel C).
Figure 4. Label-free proliferation dose-response curves with IC50 analysis. (A) Dose-response curves for multiple time points are overlaid for camptothecin, allowing time-dependent comparison of IC50 values (18 hours = 9.5 nM, 24 hours = 12.3 nM, 48 hours = 10.9 nM, and 68 hours = 8.2 nM). For each curve the 4-parameter fit is colored and the IC50 interpolation is visualized in dashed lines. (B) Gen5 provides additional estimates of IC50 values through area-under-the-curve (integral) analysis for the entire kinetic series (IC50 = 10 nM). (C) Integral-based dose-response curves for three drugs indicated. Solid lines correspond to 4-parameter fit, and dashed lines indicate IC50 interpolation. IC50 values correspond to 10 nM for camptothecin, 39 nM for nocodazole, and 193 nM for nigericin.
Fluorescence-based kinetic cell death phenotype
In addition to the overall effect on proliferation, the mechanism of cell death was examined using fluorescent reporters of apoptosis and necrosis. At each time point where brightfield images were taken, corresponding fluorescence images were taken of the apoptosis marker pSIVA and the necrosis marker PI (Figure 5A). Cells were identified positive for pSIVA and PI signals (Figure 5B) and primary masks identified individual cells for each well and time point (Figure 5B, see inset).
Figure 5. Capture and identification of cells positive for apoptosis and necrosis. (A) Example images of cells positive for pSIVA apoptosis marker (green, upper panels) and PI necrosis marker (red, lower panels) at two time points (indicated). The area of the 384-well bottom is indicated by the dashed blue outline in the top left panel of A. (B) Positive apoptotic and necrotic cells were identified by size and signal threshold parameters (see Materials and methods) and primary masks identified positive cells (inset shows enlarged region for clarity)
Quantitative analysis of apoptosis
The green fluorescence of pSIVA will increase as phosphotidylserine is exposed to the extracellular space. As expected, the number of cells positive for the apoptosis marker pSIVA increases over time in response to anti-neoplastics, but remains relatively stable at a low level in control wells (Figure 6A). Although the behavior is expected at the highest and lowest concentrations of nocodazole, at intermediate concentrations the number of cells positive for pSIVA continues to increase over time. This accumulation is due to the continued proliferation of the total cell population, despite the fact that many of the cells are actively undergoing cell death. This effect obscures the interpretation of the results, as well as left-shifts the EC50 value of the resultant dose-response curve over time (Figure 6A, bottom panel).
To control for the continued proliferation of the cells, as well as any initial variability in cell numbers between conditions and replicates, the pSIVA positive cell counts can be expressed as a percent of total cell counts established through the label-free cell counts. (Figure 6B).
Figure 6. Apoptotic signal response to anti-neoplastics. (A) Apoptotic cell counts for the drug nocodazole applied at the four concentrations indicated. Note that apoptotic cell counts continue to rise for intermediate concentrations due to total cell counts increasing. For absolute cell counts, dose-response curves were generated and fit to the three time points indicated. EC50 values were substantially left-shifted over time due to cell proliferation (EC50 24 hours = 106 nM, EC50 48 hours = 30 nM, EC50 68 hours = 17 nM). (B) The same data for apoptotic cell counts from panel A, but normalized to total cell counts (expressed as percent). For normalized apoptotic cells, all dose-response curves consistently resulted in an EC50 value of approximately 100 nM. For both A and B lower panels, Gen5 4-parameter fit lines are shown in solid colors, and EC50 interpolation lines are shown as dashed.
Importantly, normalizing apoptotic counts to total cell counts demonstrates that the percent of apoptotic cells remains stable at a given drug concentration, despite absolute increases in both label-free cell counts and pSIVA positive counts (Figure 6B, top panel). Furthermore, EC50 values at different time points are stable over time, and nearly identical for normalized counts (Figure 6B, bottom panel). Therefore, quantification of the apoptotic fluorescence signal based solely on absolute counts systematically and substantially underestimates the EC50 value over time when cells at intermediate drug concentrations continue to proliferate.
Quantitative analysis of necrosis
The kinetic apoptosis kit includes propidium iodide (PI) as a reporter of necrosis and late apoptosis. PI enters the cell and intercalates DNA when both the cellular and nuclear membranes are compromised; membrane integrity is lost both during late apoptosis and necrosis processes. Here, PI binding is monitored and quantified through fluorescence imaging. As with the pSIVA signal, PI signals generally increase over time and with increased drug dosage, as shown for nocodazole (Figure 7A). As is also seen with the pSIVA apoptosis signal, the PI positive cells also increases at intermediate drug concentrations due toproliferation. Therefore, PI positive cells were also normalized as a percent of total cells using label-free cell counts (Figure 7B).
Figure 7. Necrotic signal response to anti-neoplastics. (A) Necrotic cell counts for the drug nocodazole applied at the four concentrations indicated. Note that necrotic cell counts continue to rise for intermediate concentrations due to total cell counts increasing. (B) The same data for apoptotic cell counts from panel A, but normalized to total cell counts (expressed as percent).
For comparison and quantitation of drug efficacy, kinetic analysis and curve fitting was performed for normalized necrosis and apoptosis signals for all drugs at 24 hours (Figure 8). Interestingly, despite nigericin’s efficacy in inhibiting proliferation (IC50 = 100 nM, see Figure 4 panel C), it resulted in little apoptosis or necrosis at even the highest concentrations used, and EC50 values for apoptosis and necrosis were undetermined.
Figure 8. EC50 determination for apoptosis and necrosis. Dose-response curves for percent necrotic (left panel) and percent apoptotic cells plotted for each drug indicated. Agilent BioTek Gen5 4-parameter fits are shown for each fit (solid colored lines) as well as interpolated EC50 values (dashed lines). For apoptosis, EC50 values correspond to 24 nM for staurosporine, 121 nM for nocodazole and 301 nM for camptothecin. For necrosis, EC50 values correspond to 28 nM for staurosporine, 114 nM for nocodazole, and 301 nM for camptothecin. EC50 values for nigericin (red) were undetermined for both apoptosis and necrosis.
Additionally, the maximal plateau values for staurosporine reached higher levels for percent apoptosis, compared to percent necrosis, despite similarities in the EC50 values for both processes. This difference potentially indicates that staurosporine preferentially initiates apoptosis in HT-1080 cells. Therefore quantitative investigation into the onset time of the apoptosis and necrosis signals was also performed using Gen5.
In Figure 9, panel A, traces of percent apoptosis and percent necrosis are both shown for staurosporine (blue) and camptothecin (green). By eye, for cells treated with staurosporine the apoptosis signal precedes the necrosis signal. For comparison, the percent apoptosis and necrosis signals onset times are nearly identical for camptothecin, as both traces overlap significantly. To quantify this difference, the time of Vmax parameter was measured for each trace (see Materials and Methods for details). To evaluate time of Vmax for each drug, the first concentration approaching maximal levels of percent apoptosis and necrosis was chosen. The time of Vmax for each drug is shown in Figure 9, panel B. Only staurosporine showed an onset time difference between the two signals, with apoptosis proceeding necrosis by ~3.5 hours. This finding indicates that the mechanism of cell death is primarily through apoptosis, leading to necrosis.
Figure 9. Onset time comparison for apoptosis and necrosis processes. (A) Example traces for apoptosis signal (filled circles) and necrosis signal (open circles) plotted together for the same cell population. For staurosporine (blue traces), but not camptothecin (green traces), apoptosis proceeds necrosis signals. (B) Plot comparing time of Vmax parameter for apoptosis (abbreviated as “A”) and necrosis (abbreviated as “N”). Only staurosporine showed a significant (p=0.000001) difference between time of Vmax, with apoptosis occurring ~3.5 hours earlier than necrosis.
The Agilent BioTek Cytation 5 cell imaging multimode reader with wide-field-of-view camera, paired with an Agilent BioTek BioSpa automated incubator, provides a fully automated and robust means of quantifying image-based assays of cell proliferation and cell death. The wide-field-of-view camera allows single image capture of whole-well culture area, minimizing image capture time and improving compatibility for small culture area vessels for high-throughput applications. Agilent BioTek Gen5 software and cell analysis routines allow for quick, automated identification of cell counts, for both brightfield and fluorescence-based images. Normalization of fluorescence signals using the label-free cell counts was critical to avoid bias in EC50 determination due to differences in proliferation rates between conditions.
1. Hanahan, D. and Weinberg, R.A. (2011). The Hallmarks of Cancer: The Next Generation. Cell, 144 (5): 646-674. doi 10.1016/j.cell.2011.02.013
2. Galluzzi, L., Vitale I. et al. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 25: 486-541. doi.org/10.1038/s41418-017-0012-4
3. Segawa, K., Nagata S. (2015). An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine Exposure. Trends in Cell Biology, 25 (11); 639-650. doi.org/10.1016/j.tcb.2015.08.003
4. Kim, Y.E., Chen J., Chan J.R., Langen R. (2010) Engineering a polarity-sensitive biosensor for time-lapse imaging of apoptotic processes and degeneration. Nature Methods, 7; 67-73. doi.org/10.1038/nmeth.1405
5. Clayton, J. (2017) Kinetic Proliferation Assay using Label-Free Cell Counting. BioTek Resources https://www.biotek.com/resources/application-notes/kinetic-proliferation-assay-using-label-free-cell-counting/.